Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias

被引:12
|
作者
Kaplan, AA [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Div Nephrol, Dept Med, Farmington, CT 06030 USA
来源
THERAPEUTIC APHERESIS | 2001年 / 5卷 / 03期
关键词
multiple myeloma; mixed cryoglobinemia; membranoproliferative glomerulonephritis; macroglobulinemia; therapeutic plasma exchange;
D O I
10.1046/j.1526-0968.2001.00301.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disordered immunoglobulin synthesis can result in a variety of different types of renal pathology. Multiple myeloma is often associated with the overproduction of light chains which may result in toxicity to the renal tubules and acute renal failure. Patients with mixed cryoglobulinemia will have renal involvement which is most often in the form of a membranoproliferative glomerulonephritis. Renal involvement in macroglobulinemia is relatively uncommon, but IgM thrombi can be so voluminous as to occlude the glomerular capillary lumen. In each of these examples, therapeutic plasma exchange has been found to be a useful adjunct to the eventual chemotherapy required for the definitive treatment of these disorders.
引用
收藏
页码:171 / 175
页数:5
相关论文
共 50 条
  • [41] Apoptotic Signaling in Multiple Myeloma: Therapeutic Implications
    Dharminder Chauhan
    Teru Hideshima
    Kenneth C. Anderson
    International Journal of Hematology, 2003, 78 : 114 - 120
  • [42] Therapeutic strategies and controversies in the treatment of multiple myeloma
    Bladé, J
    PATHOLOGIE BIOLOGIE, 1999, 47 (02): : 192 - 198
  • [43] Multiple myeloma: therapeutic delivery of antibodies and aptamers
    Pujol-Navarro, Neret
    Al Qaraghuli, Mohammed M.
    Kubiak-Ossowska, Karina
    Alsaadi, Manal M.
    Horne, Gillian A.
    Soutar, Richard L.
    Paspali, Elpiniki
    Ferro, Valerie A.
    Williams, Mark T. S.
    Mulheran, Paul A.
    THERAPEUTIC DELIVERY, 2021, 12 (10) : 705 - 722
  • [44] A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange
    Post, Ginell R.
    James, Lindsey
    Alapat, Daisy
    Guillory, Virginia
    Cottler-Fox, Michele
    Nakagawa, Mayumi
    TRANSFUSION AND APHERESIS SCIENCE, 2013, 48 (01) : 35 - 38
  • [45] CircRNAs: novel therapeutic targets in multiple myeloma
    Xinyi Zhou
    Juan Du
    Molecular Biology Reports, 2022, 49 : 10667 - 10676
  • [46] An emergency medicine review: Multiple myeloma and its complications
    Long, Brit
    Mccurdy, Arleigh
    Koyfman, Alex
    Rosenberg, Hans
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2025, 88 : 172 - 179
  • [47] Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
    Cole, Daniel C.
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2018, 26 (03) : 122 - 129
  • [48] Therapeutic Effect and Adverse Event Rate of Different Treatment Methods in Patients with Multiple Myeloma and Renal Insufficiency
    Cui, Lijuan
    Ning, Jing
    Yang, Rui
    Wang, Hainan
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2024, 185 (07) : 659 - 667
  • [49] Diagnostic delay and complications for older adults with multiple myeloma
    Friese, Christopher R.
    Abel, Gregory A.
    Magazu, Lysa S.
    Neville, Bridget A.
    Richardson, Lisa C.
    Earle, Craig C.
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 392 - 400
  • [50] Thalidomide in patients with multiple myeloma and renal failure
    Fakhouri, F
    Guerraoui, H
    Presne, C
    Peltier, J
    Delarue, R
    Muret, P
    Knebelmann, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 96 - 97